Show simple item record

dc.contributor.authorKohn, David
dc.date.accessioned2017-08-17T16:54:30Z
dc.date.available2017-08-17T16:54:30Z
dc.date.issued2016-12-23
dc.identifier.urihttp://hdl.handle.net/10713/6972
dc.descriptionNews release announcing the successful results of an experimental Ebola vaccine in a 2015 trial in Guinea, West Africa. Investigators from the UMB School of Medicine’s Center for Vaccine Development (CVD) and its field site in Mali participated in training field workers in the principles of Good Clinical Practice. The rVSV-ZEBOV vaccine manufactured by Merck, Sharpe & Dohme, was administered to 5,837 people in the project that was led by the World Health Organization (WHO). The results of the trial were published in the journal, Lancet (Vol. 389, no. 10068, Feb. 4, 2017).
dc.language.isoen_USen_US
dc.subjectrVSV-ZEBOVen_US
dc.subjectUniversity of Maryland, Baltimore. Center for Vaccine Development (CVD)en_US
dc.subject.lcshGuineaen_US
dc.subject.lcshMerck Sharp & Dohmeen_US
dc.subject.meshHemorrhagic Fever, Ebola--prevention & controlen_US
dc.subject.meshEbola Vaccines--therapeutic useen_US
dc.titleEbola Vaccine Called 100% Effectiveen_US
dc.title.alternativeEbola Vaccine Called One Hundred Percent Effective
dc.typeArticleen_US
dc.description.urinameFull Texten_US
refterms.dateFOA2019-02-19T18:29:52Z


Files in this item

Thumbnail
Name:
EbolaVaccine_UMB2016.pdf
Size:
308.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record